Table 9 Observed cancer cases for the MSH6 cohort with 100% or 50% probability of MMR mutation (excluding colorectal and endometrial cancer)
From: A retrospective study of extracolonic, non-endometrial cancer in Swedish Lynch syndrome families
Primary cancer | Observed number | Proportion [%] | LL 95% | UL 95% | Proportion [%] in Sweden 1970 | Proportion [%] in Sweden 2010 | Reference outside CI |
|---|---|---|---|---|---|---|---|
Breast | 16 | 17.78 | 10 | 25.56 | 21.31 | 29.43 | No |
Ovary and Fallopian tube | 14 | 15.56 | 8.89 | 23.33 | 6.4 | 2.6 | above |
Prostate | 13 | 14.44 | 7.78 | 22.22 | 5.5 | 11.58 | No |
Kidney/urinary tract excl prostate | 10 | 11.11 | 5.56 | 17.78 | 8.24 | 5.57 | No |
Stomach | 8 | 8.89 | 3.33 | 15.56 | 6.74 | 1.38 | No |
Brain and nervous system | 8 | 8.89 | 3.33 | 15.56 | 4.88 | 4.16 | No |
Blood and lymphatic tissue | 7 | 7.78 | 2.22 | 13.33 | 8.66 | 8.21 | No |
Cervix | 4 | 4.44 | 1.11 | 8.89 | 5.93 | 1.79 | No |
Liver and biliary system | 3 | 3.33 | 0 | 7.78 | 3.14 | 1.71 | No |
Pancreas | 2 | 2.22 | 0 | 5.56 | 3.23 | 1.85 | No |
Lung and airways | 2 | 2.22 | 0 | 5.56 | 6.49 | 7 | below |
Skin excl melanom | 1 | 1.11 | 0 | 3.33 | 1.96 | 5.44 | No |
Endocrine cancer | 1 | 1.11 | 0 | 3.33 | 2.17 | 1.81 | No |
Bone and soft tissue | 1 | 1.11 | 0 | 3.33 | 1.24 | 0.83 | No |
Head and neck | 0 | 0 | 0 | 0 | 2.94 | 2.55 | below |
Oesophagus | 0 | 0 | 0 | 0 | 0.75 | 0.54 | below |
Small bowel | 0 | 0 | 0 | 0 | 0.5 | 0.56 | below |
female genital organ | 0 | 0 | 0 | 0 | 0.72 | 0.46 | below |
Testicle | 0 | 0 | 0 | 0 | 0.49 | 0.9 | below |
Penis | 0 | 0 | 0 | 0 | 0.18 | 0.11 | below |
Malign melanom | 0 | 0 | 0 | 0 | 3 | 7.23 | below |
Eye | 0 | 0 | 0 | 0 | 0.47 | 0.34 | below |
Thyroid | 0 | 0 | 0 | 0 | 1.35 | 1.59 | below |
Unspecified location | 0 | 0 | 0 | 0 | 3.72 | 2.37 | below |